Zolgensma ‘Lottery’ Attacked From All Sides
Fears It Could Damage Pharma Industry’s Reputation
An unusual managed access program for Zolgensma designed by Novartis and AveXis has been attacked on ethical grounds, with critics claiming it does not properly allot the gene therapy to patients most in need. The companies have rejected the criticism, saying the program is fair and equitable.
